

Cuba awards humanized monoclonal antibody Nimotuzumab



Nimotuzumab was safe in the treatment of patients with Covid-19. Photo: Cuban Medical Services

Havana, Jan 11 (RHC) The Science, Technology and Environment Ministry (CITMA) awarded Cuba's Center for Molecular Immunology (CIM) for research on the humanized monoclonal antibody Nimotuzumab.

The award was granted to the greatest scientific project, in this case, Nimotuzumab that has been used for treating Covid-19 patients.

According to a message from the Center for Molecular Immunology on Twitter, "CITMA Special Award went to the title Repositioning of the Cuban humanized monoclonal antibody Nimotuzumab for treating Covid-19 patients".

CITMA and CIM strategic integration have made this scientific research a reality, the scientific institution recalled.

According to CIM's Clinical Research Director Tania Crombet, Nimotuzumab was safe in the treatment of patients with Covid-19, proving an improved ventilatory function and a decreased inflammation marker.

After being applied to Covid-19 patients, results found evidence of an 80% of radiological recovery or stabilization of multifocal pneumonia on the seventh day of treatment.

Unlike other innovative molecules to be used for treating Covid-19, Nimotuzumab could have a key anti-inflammatory role, and also have an impact on reestablishing the coagulation disorder as well as preventing or reversing pulmonary fibrosis, Crombet pointed out. (Source: Prensa Latina).

<https://www.radiohc.cu/en/noticias/nacionales/310266-cuba-awards-humanized-monoclonal-antibody-nimotuzumab>



Radio Habana Cuba